In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on Denali Therapeutics Inc (DNLI – Research Report), with a price target of $25. The company’s shares closed yesterday at $18.94.
“We reiterate our Overweight rating and 12-month PT of $27/ share of DNLI. Denali is holding an R&D day on December 10th, where it will discuss perspectives on recent innovation for neurodegenerative molecules it has engineered for brain delivery, biomarker-driven development, and progress in its two clinical-stage programs targeting LRRK2 and RIPK1.”
According to TipRanks.com, Duncan is a 1-star analyst with an average return of -0.7% and a 44.1% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Denali Therapeutics Inc is a Strong Buy with an average price target of $27.50.
Based on Denali Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $35.37 million. In comparison, last year the company had a GAAP net loss of $21.84 million.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DNLI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Denali Therapeutics, Inc. engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis.